KEYNOTE SPEAKERS
|
Jill Buckley, MD, MBA |
Jill Buckley, MD, is a board-certified, urologic trauma reconstruction surgeon. Her clinical and research expertise focus on urethral reconstruction, including urinary fistula repair, complications from prostate cancer therapy, and genitourinary reconstruction for urethral stricture. As an associate professor of surgery and urology residency program director, Dr. Buckley is involved in training residents and fellows in urology at UC San Diego School of Medicine. Prior to her arrival at UC San Diego Health, Dr. Buckley was an assistant professor at Tufts University School of Medicine and on the faculty at Lahey Clinic Medical Center. During her medical education and training, Dr. Buckley completed a fellowship in reconstructive and trauma surgery, as well as her residency in urology, at UC San Francisco. She earned both her medical degree and her bachelor’s degree in physiological science from UC Los Angeles. Dr. Buckley is a fellow of the American College of Surgeons, a member of the American Urological Association, and serves on the Board of the Society of Genitourinary Reconstructive Surgeons. She has co-authored numerous research studies and several surgical textbooks on urethral reconstruction, acute urinary trauma management and genitourinary reconstruction. She is also a member of the Trauma and Urinary Reconstructive Network of Surgeons (TURNS). |
||
|
Sia Daneshmand, MD |
Dr. Sia Daneshmand is currently Professor of Urology and Medicine (Oncology) with Clinical Scholar designation and serves as director of urologic oncology, as well as the urologic oncology (SUO) fellowship director at the University of Southern California (USC) in Los Angeles. His main clinical interests include bladder cancer, testicular cancer, and advanced kidney cancer. He is a leading authority in the management of complex germ cell tumors and nerve-sparing retroperitoneal lymph node dissection (RPLND) following chemotherapy for advanced testicular cancer and is one of the highest volume surgeons for this disease in the country. His main research interests focus on the use of pathways to improve peri-operative outcomes following radical cystectomy and post-chemo RPLND, use of serum and molecular markers and new technologies in diagnosis and management of bladder and testicular cancers, as well as functional outcomes following orthotopic urinary diversion. He serves on the AUA Guidelines panel for non-muscle invasive bladder cancer, as well as the AUA Guidelines panel for Testicular cancer. He currently serves as the chair of bladder section of the SUO Clinical Trials Consortium (SUO-CTC), is on the scientific steering committee of several bladder cancer clinical trials and has led over a dozen clinical trials in bladder cancer and a pivotal trial in testicular cancer (SEMS). He was recently appointed. He is current secretary of the Western Section of the AUA. He is a member of Alpha Omega Alpha medical honor society and has been designated one of the “America’s Top Cancer Doctors” for the past 12 consecutive years. He has been a career leader in academic investigations in bladder cancer and germ cell tumors and was recently appointed as the chair of the SWOG local bladder committee. He has been a visiting professor at more than 25 institutions around the world. He has presented over 500 abstracts at scientific meetings and has authored over 375 peer-reviewed articles, reviews, and book chapters. | ||
|
Brian Ferguson |
Brian Ferguson has spent his career working in high-performance organizations, learning from leaders and decision-makers in US national security, the military, and technology. He has used those experiences to build Arena Labs, a company pioneering the field of High Performance Medicine ®. Arena Labs is on a mission to reimagine healthcare by treating doctors and nurses as elite performers. By investing in clinicians with the same training, tools and technology as elite military personnel, Olympic athletes, and creative masters, Arena Labs believes hospitals can reduce burnout and provide healthcare teams with the ability to flourish in the face of a demanding, stressful career. Brian is also a Partner + Co-Founder of the Liminal Collective, a unique company human performance focused company “enabling humanity’s boldest endeavors.” Liminal is currently working in civilian space travel, deep sea exploration, and the digital future of cyberspace. Before founding Arena Labs + Liminal Collective, Brian served in the military as a Navy SEAL Officer where he deployed to Afghanistan and various parts of the Middle East. Prior to joining the military, he was a Presidential Appointee in the Office of the Secretary of Defense and worked in the White House. Brian serves on faculty at Singularity University in Silicon Valley, working with Fortune 500 leaders on challenges related to exponential technology and change. He also co-chairs the “Limits of Human Performance” symposia at the Santa Fe Institute on Complexity and is a member of the Council on Foreign Relations. He received an MSc from The London School of Economics and speaks intermediate Persian/Farsi. Brian serves on the Boards of Alder, Seatrec, and The Honor Foundation. He lives in Nashville, Tennessee and is most proud of being father to his daughter, Wynnen Valentine. |
||
|
David Goldfarb, MD |
Dr. David S. Goldfarb is Professor of Medicine and Physiology at NYU Grossman School of Medicine, Clinical Chief of the Nephrology Division at NYU Langone Health, and Chief of the Nephrology Section at the New York VA Medical Center in Manhattan. He serves as the Director of the Kidney Stone Prevention Program at NYU Langone and at New York VA Medical Center. He graduated from Yale College and the Yale School of Medicine and trained in Internal Medicine at New York VA and NYU, and Nephrology at New York University. He is a principal investigator of the Rare Kidney Stone Consortium and served as President of the NY Society of Nephrology (1999) and of the ROCK Society (Research on Calculus Kinetics, 2016). He was vice-chair of the American Urological Association’s guideline panel, on Medical Management of Kidney Stones, representing the American Society of Nephrology, and co-authored the ensuing guidelines. He was selected “Stone Crusher of the Year” in 2014 by the Oxalosis and Hyperoxaluria Foundation and “Nephrologist of the Year” in 2016 by the American Kidney Fund. He has had three calcium oxalate stones. | ||
|
Anne Suskind, MD, MS |
Anne M. Suskind, MD, MS received her undergraduate training at Haverford College, where she earned a bachelor degree in Anthropology with honors investigating the anthropological influences surrounding women’s health issues. She next graduated a distinction in Bioethics from Albany Medical College’s MD program. Dr. Suskind completed her General Surgery and Urology training at the University of Connecticut. She subsequently completed two fellowships at the University of Michigan, one in Neurourology & Pelvic Reconstructive Surgery the other in Health Services Research. During her fellowship training, Dr. Suskind obtained a Masters’ Degree in Clinical Research Design and Statistical Analysis from the University of Michigan’s Rackham School of Graduate Studies and was funded by a T32 grant from the National Institutes of Health (NIH). Her past and current funding includes the Elisabeth Pickett Research Award from the Society of Women in Urology (SWIU), the Thomas Benson Award in Neuromodulation from the American Urogynecologic Society (AUGS), the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) Research Foundation Grant for the Study of Overactive Bladder and Urinary Incontinence, an R03 from the National Institute on Aging (NIA-NIH) and a K12 grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK-NIH). She has received many honors for her research including the 2016 New Investigator Award from the American Geriatrics Society (AGS) and the 2017 Jeffrey H. Sliverstein Memorial Award for Emerging Investigators in the Surgical and Related Medical Specialties that are Focused on the Care of older Adults also from the AGS. In 2014, Dr. Suskind became an Assistant Professor in the Department of Urology at the University of California, San Francisco, where she currently works at the Parnassus campus. In 2018, she became an Associate Professor and recently, in 2020 she became Chief of Neurourology, Female Pelvic Medicine & Reconstructive Surgery and Director of Faculty Development. | ||
